Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06416410 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years later Sep 30, 2026 → Sep 30, 2029
See other at-risk trials from Allist Pharmaceuticals, Inc.

Record History

  1. Primary completion pushed from Sep 30, 2026 to Sep 30, 2029
    • Study completion pushed from Feb 28, 2027 to Aug 2030
    v6
  2. Study Identification, Study Status, Contacts/Locationsv5
  3. Lead sponsor: Jacobio Pharmaceuticals Co., Ltd. to Allist Pharmaceuticals, Inc.v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 37
    • Start date changed from estimate of Jul 17, 2024 to Aug 7, 2024
    v3
  5. Interventions: Carboplatin (Drug), JAB-21822 (Drug), JAB-3312 (Drug), Pemetrexed (Drug), Tirellizumab (Drug) to Carboplatin (Drug), JAB-21822 (Drug), JAB-3312 (Drug), Pemetrexed (Drug), Tislelizumab (Drug)v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06416410
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Enrollment 392 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov